



K013481

GE Medical Systems
P.O. Box 414, W-709
Milwaukee, WI 53201 USA

NOV 02 2001

510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

This 510(k) summary of safety and effectiveness information is submitted in accordance with the requirements of 21 CFR Pat 807.87(h).

Identification of Submitter: Larry A. Kroger, Ph.D.
Senior Regulatory Programs Manager
GE Medical Systems
Tel. (414) 544-3894
Summary prepared: 19 February, 2001

Identification of Product: Dual Energy and Tissue Equalization Software Options for Digital Radiographic Systems
Classification Name: Stationary X-ray System
Manufacturer: GE Medical Systems
3000 N. Grandview Blvd.
Waukesha, WI 53118

Device Description: Dual Energy is a technique whereby two images are acquired at different x-ray energies and then used to create two derived images, for example soft tissue and bone.

The Tissue equalization algorithm is used to enhance the contrast in thick areas while maintaining suitable contrast in the primary area of interest.

Indications for Use: Dual Energy and Tissue Equalization software options are intended for use in generating digital radiographic images of human anatomy, *EXCEPT MAMMOGRAMS.*

Comparison with: Dual Energy and Tissue Equalization software options are substantially equivalent to the Dual Energy and Tissue Equalization software options for use on the Revolution XR/d Digital Radiographic Imaging System (K012389).

Conformance: Dual Energy and Tissue Equalization software options will conform to applicable sections of 21CFR 1020.30 and 1020.31. The software options will also conform to IEC 601-1-4.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room – WO66-G609
Silver Spring, MD 20993-0002

General Electric Medical Systems
% Mr. Reiner Krumme
Manager, Medical Division
TUV Rheinland of North America
12 Commerce Road
NEWTOWN CT 06470

AUG 21 2013

Re: K013481

Trade/Device Name: Dual Energy and Tissue Equalization Software Option
Regulation Number: 21 CFR 892.1680
Regulation Name: Stationary x-ray system
Regulatory Class: II
Product Code: KPR
Dated: October 16, 2001
Received: October 19, 2001

Dear Mr. Krumme:

This letter corrects our substantially equivalent letter of November 2, 2001.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely Yours,



Janine M. Morris
Acting Director
Division of Radiological Devices
Office of In Vitro Diagnostic Device
Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

